Protagonist Therapeutics, Inc (PTGX) Stock Price

PTGXStock

$128.75+70.01%52W

Market Cap$8.33B

P/E21.85x

PEG Ratio—

Div yield—

Beta1.20

PTGX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)13.04%

Price vs S&P 500 (4W)-9.87%

VGM Score53.74

P/E Ratio (Annual)21.85x

P/CF (Annual)144.46x

Book Value / Share (Quarterly)$13.01

P/TBV (Annual)4.61x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)20.07%

Cash Flow / Share (Quarterly)$2.02

Price vs S&P 500 (YTD)35.49%

Net Profit Margin (TTM)29.40%

EPS (TTM)$1.04

10-Day Avg Trading Volume0.88M

EPS Excl Extra (TTM)$1.04

Revenue Growth (5Y)9.96%

EPS (Annual)$-2.05

ROI (Annual)-21.17%

Net Profit Margin (5Y Avg)-257.85%

Cash / Share (Quarterly)$12.10

P/E Basic Excl Extra (TTM)100.49x

Revenue Growth QoQ (YoY)3749.17%

P/E Normalized (Annual)21.85x

ROA (Last FY)-19.48%

Revenue Growth TTM (YoY)34.81%

EBITD / Share (TTM)$0.89

ROE (5Y Avg)-20.96%

Operating Margin (TTM)20.69%

Cash Flow / Share (Annual)$0.90

P/B Ratio9.90x

P/B Ratio (Quarterly)9.37x

Net Income / Employee (Annual)$-986,000

EV / Revenue (TTM)28.05x

Net Interest Coverage (TTM)-7.30x

ROA (TTM)11.23%

EV / EBITDA (TTM)132.11x

EPS Incl Extra (Annual)$-2.05

Current Ratio (Annual)12.71x

Quick Ratio (Quarterly)21.58x

3-Month Avg Trading Volume0.71M

52-Week Price Return70.01%

EV / Free Cash Flow (Annual)141.07x

P/E Incl Extra (TTM)100.49x

Revenue / Employee (TTM)$2,136,300

Tangible BV / Share (Quarterly)$5.24

P/S Ratio (Annual)181.05x

Asset Turnover (Annual)0.07x

52-Week High$160.81

Operating Margin (5Y Avg)-279.15%

EPS Excl Extra (Annual)$-2.05

CapEx CAGR (5Y)27.60%

Tangible BV CAGR (5Y)12.32%

26-Week Price Return22.95%

Quick Ratio (Annual)12.58x

13-Week Price Return-8.63%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)21.71x

Enterprise Value$7.91B

Revenue / Share Growth (5Y)-2.75%

Asset Turnover (TTM)0.38x

Book Value / Share Growth (5Y)8.95%

Revenue / Employee (Annual)$348,600

Pretax Margin (Annual)-281.01%

Cash / Share (Annual)$9.07

3-Month Return Std Dev38.03%

Net Income / Employee (TTM)$628,100

ROE (Last FY)-21.17%

Net Interest Coverage (Annual)-376.80x

EPS Basic Excl Extra (Annual)$-2.05

P/FCF (TTM)38.06x

Receivables Turnover (TTM)16.54x

EV / Free Cash Flow (TTM)60.58x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$1.04

Receivables Turnover (Annual)9.87x

ROI (TTM)12.03%

P/S Ratio (TTM)29.54x

Pretax Margin (5Y Avg)-257.29%

Revenue / Share (Annual)$0.72

Tangible BV / Share (Annual)$4.37

Forward P/E269.04x

Price vs S&P 500 (52W)54.48%

P/E Ratio (TTM)100.49x

EPS Growth TTM (YoY)45.97%

Year-to-Date Return47.41%

5-Day Price Return-11.13%

EPS Normalized (Annual)$-2.05

ROA (5Y Avg)-18.42%

Net Profit Margin (Annual)-282.83%

Month-to-Date Return-8.62%

Cash Flow / Share (TTM)$-2.59

EBITD / Share (Annual)$-2.47

Operating Margin (Annual)-343.63%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)63.50x

ROI (5Y Avg)-20.96%

P/E Excl Extra (TTM)100.49x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$1.04

P/TBV (Quarterly)3.29x

P/B Ratio (Annual)8.88x

Pretax Margin (TTM)29.91%

Book Value / Share (Annual)$9.82

Price vs S&P 500 (13W)-11.31%

Beta1.20x

P/FCF (Annual)148.56x

Revenue / Share (TTM)$3.97

ROE (TTM)12.03%

52-Week Low$73.08

vGradeF

gGradeB

mGradeB

vgmGradeC

PTGX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	$1.93	$2.29	+18.72%(+$0.36)
Q1 2026	May 5, 2026	-$0.65	$0.05	+107.64%(+$0.70)
Q4 2025	Feb 25, 2026	-$0.54	-$0.69	-27.43%(-$0.15)
Q3 2025	Nov 6, 2025	-$0.64	-$0.62	+3.65%(+$0.02)
Q2 2025	Aug 6, 2025	-$0.52	-$0.55	-4.77%(-$0.03)

PTGX Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.25

4.30

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78
MIRMMirum Pharmaceuticals, Inc. Common Stock	F	B	C	8.4x	44.0%	81.7%	—	$80.14

About Protagonist Therapeutics, Inc

Protagonist Therapeutics is a biopharmaceutical company developing peptide-based therapeutics across inflammation, hematology, and metabolic diseases using a proprietary platform. Its clinical pipeline includes rusfertide for polycythemia vera and icotrokinra for inflammatory conditions, complemented by preclinical programs in obesity and iron metabolism. The company advances its candidates through internal research and strategic collaborations.

PTGX Next Earnings Report

Report dateNov 5, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate$2.53

Revenue estimate$232.04M

Also reporting on Nov 5, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

PTGX Insider Transactions

SellSep 10, 2026
PATEL DINESH V
Chief Executive Officer
Shares: 125,000Value: $18.24M
SellAug 11, 2026
PATEL DINESH V
Chief Executive Officer
Shares: 100,000Value: $14.89M

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

KRYSKrystal Biotech, Inc. Common StockBiological Products
TWSTTwist Bioscience Corporation Common StockBiological Products
KYMRKymera Therapeutics, Inc. Common StockBiological Products
ESIElement Solutions Inc.Industrial Chemicals
WLKWestlake CorporationIndustrial Chemicals
NEUNewMarket CorporationIndustrial Chemicals
AXTAAxalta Coating Systems Ltd.Paints & Coatings
EMNEastman Chemical CompanyPlastics & Resins

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.3

Strong Buy

Consensus rating

52-Week Range

Low$73.08

High$160.81